Lantheus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 07:51 am EDT
Share
Lantheus Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 239.29 million compared to USD 102.07 million a year ago. Net income was USD 61.23 million compared to net loss of USD 13.42 million a year ago. Basic earnings per share from continuing operations was USD 0.89 compared to basic loss per share from continuing operations of USD 0.2 a year ago. Diluted earnings per share from continuing operations was USD 0.86 compared to diluted loss per share from continuing operations of USD 0.2 a year ago.
For the nine months, sales was USD 671.9 million compared to USD 295.65 million a year ago. Net income was USD 147.25 million compared to net loss of USD 31.06 million a year ago. Basic earnings per share from continuing operations was USD 2.15 compared to basic loss per share from continuing operations of USD 0.46 a year ago. Diluted earnings per share from continuing operations was USD 2.08 compared to diluted loss per share from continuing operations of USD 0.46 a year ago.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
LANTHEUS HOLDINGS, INC. 
